Roth Capital Predicts Clene’s Q1 Earnings (NASDAQ:CLNN)

Clene Inc. (NASDAQ:CLNN) – Analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of Clene in a research note issued to investors on Wednesday, November 13th. Roth Capital analyst J. Aschoff expects that the company will post earnings of ($0.86) per share for the quarter. The consensus estimate for Clene’s current full-year earnings is ($5.26) per share. Roth Capital also issued estimates for Clene’s Q2 2025 earnings at ($0.86) EPS, Q3 2025 earnings at ($0.85) EPS and Q4 2025 earnings at ($0.75) EPS.

Other research analysts also recently issued reports about the company. EF Hutton Acquisition Co. I raised Clene to a “strong-buy” rating in a research report on Tuesday, September 10th. Canaccord Genuity Group dropped their price objective on shares of Clene from $86.00 to $83.00 and set a “buy” rating on the stock in a report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Clene in a research note on Thursday.

Clene Trading Down 3.4 %

Clene stock opened at $4.53 on Friday. The business’s 50-day simple moving average is $5.43 and its 200-day simple moving average is $6.03. Clene has a 52 week low of $3.82 and a 52 week high of $12.00. The firm has a market capitalization of $31.06 million, a PE ratio of -0.86 and a beta of 0.42. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.99 and a current ratio of 0.99.

Insiders Place Their Bets

In related news, Director David J. Matlin bought 92,307 shares of the company’s stock in a transaction dated Monday, September 30th. The stock was acquired at an average cost of $4.75 per share, with a total value of $438,458.25. Following the acquisition, the director now owns 444,491 shares in the company, valued at approximately $2,111,332.25. This represents a 26.21 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Mortenson purchased 20,512 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The stock was bought at an average cost of $4.75 per share, for a total transaction of $97,432.00. Following the purchase, the insider now owns 28,949 shares in the company, valued at $137,507.75. This represents a 243.12 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 25.10% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Clene stock. Castleview Partners LLC purchased a new stake in shares of Clene Inc. (NASDAQ:CLNN) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 12,783 shares of the company’s stock, valued at approximately $59,000. Castleview Partners LLC owned about 0.19% of Clene as of its most recent SEC filing. 23.28% of the stock is currently owned by institutional investors and hedge funds.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.